Cargando…
Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
Multiple myeloma (MM) is characterized by heterogeneity of tumor cells. The study of tumor cells from blood, bone marrow, plasmacytoma, etc., allows us to identify similarities and differences in tumor lesions of various anatomical localizations. The aim of this study was to compare the loss of hete...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957234/ https://www.ncbi.nlm.nih.gov/pubmed/36833278 http://dx.doi.org/10.3390/genes14020351 |
_version_ | 1784894775574396928 |
---|---|
author | Soloveva, Maiia Solovev, Maksim Nikulina, Elena Risinskaya, Natalya Biderman, Bella Yakutik, Igor Obukhova, Tatiana Mendeleeva, Larisa |
author_facet | Soloveva, Maiia Solovev, Maksim Nikulina, Elena Risinskaya, Natalya Biderman, Bella Yakutik, Igor Obukhova, Tatiana Mendeleeva, Larisa |
author_sort | Soloveva, Maiia |
collection | PubMed |
description | Multiple myeloma (MM) is characterized by heterogeneity of tumor cells. The study of tumor cells from blood, bone marrow, plasmacytoma, etc., allows us to identify similarities and differences in tumor lesions of various anatomical localizations. The aim of this study was to compare the loss of heterozygosity (LOH) by tumor cells by assessing STR profiles of different MM lesions. We examined paired samples of plasma circulating tumor DNA (ctDNA) and CD138+ bone marrow cells in MM patients. For patients with plasmacytomas (66% of 38 patients included), the STR profile of plasmacytomas was also studied when biopsy samples were available. Diverse patterns of LOH were found in lesions of different localization for most patients. LOH in plasma ctDNA, bone marrow, and plasmacytoma samples was found for 55%, 71%, and 100% of patients, respectively. One could expect a greater variety of STR profiles in aberrant loci for patients with plasmacytomas. This hypothesis was not confirmed—no difference in the frequency of LOH in MM patients with or without plasmacytomas was found. This indicates the genetic diversity of tumor clones in MM, regardless of the presence of extramedullar lesions. Therefore, we conclude that risk stratification based on molecular tests performed solely on bone marrow samples may not be sufficient for all MM patients, including those without plasmacytomas. Due to genetic heterogeneity of MM tumor cells from various lesions, the high diagnostic value of liquid biopsy approaches becomes obvious. |
format | Online Article Text |
id | pubmed-9957234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99572342023-02-25 Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma Soloveva, Maiia Solovev, Maksim Nikulina, Elena Risinskaya, Natalya Biderman, Bella Yakutik, Igor Obukhova, Tatiana Mendeleeva, Larisa Genes (Basel) Article Multiple myeloma (MM) is characterized by heterogeneity of tumor cells. The study of tumor cells from blood, bone marrow, plasmacytoma, etc., allows us to identify similarities and differences in tumor lesions of various anatomical localizations. The aim of this study was to compare the loss of heterozygosity (LOH) by tumor cells by assessing STR profiles of different MM lesions. We examined paired samples of plasma circulating tumor DNA (ctDNA) and CD138+ bone marrow cells in MM patients. For patients with plasmacytomas (66% of 38 patients included), the STR profile of plasmacytomas was also studied when biopsy samples were available. Diverse patterns of LOH were found in lesions of different localization for most patients. LOH in plasma ctDNA, bone marrow, and plasmacytoma samples was found for 55%, 71%, and 100% of patients, respectively. One could expect a greater variety of STR profiles in aberrant loci for patients with plasmacytomas. This hypothesis was not confirmed—no difference in the frequency of LOH in MM patients with or without plasmacytomas was found. This indicates the genetic diversity of tumor clones in MM, regardless of the presence of extramedullar lesions. Therefore, we conclude that risk stratification based on molecular tests performed solely on bone marrow samples may not be sufficient for all MM patients, including those without plasmacytomas. Due to genetic heterogeneity of MM tumor cells from various lesions, the high diagnostic value of liquid biopsy approaches becomes obvious. MDPI 2023-01-29 /pmc/articles/PMC9957234/ /pubmed/36833278 http://dx.doi.org/10.3390/genes14020351 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Soloveva, Maiia Solovev, Maksim Nikulina, Elena Risinskaya, Natalya Biderman, Bella Yakutik, Igor Obukhova, Tatiana Mendeleeva, Larisa Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma |
title | Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma |
title_full | Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma |
title_fullStr | Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma |
title_full_unstemmed | Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma |
title_short | Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma |
title_sort | loss of heterozygosity in the circulating tumor dna and cd138+ bone marrow cells in multiple myeloma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957234/ https://www.ncbi.nlm.nih.gov/pubmed/36833278 http://dx.doi.org/10.3390/genes14020351 |
work_keys_str_mv | AT solovevamaiia lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma AT solovevmaksim lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma AT nikulinaelena lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma AT risinskayanatalya lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma AT bidermanbella lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma AT yakutikigor lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma AT obukhovatatiana lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma AT mendeleevalarisa lossofheterozygosityinthecirculatingtumordnaandcd138bonemarrowcellsinmultiplemyeloma |